



ABN 82 010 975 612

Level 27, 101 Collins Street  
Victoria 3000 Australia  
Telephone: + 61 7 3088 7926  
Facsimile: + 61 7 3394 4394  
[www.tbgbio.com](http://www.tbgbio.com)

18 March 2021

**ASX Announcement**  
**ASIC's Determination under s713(6) of the Corporations Act 2001**

On 12 March 2021, the Australian Securities and Investments Commission (ASIC) made a determination pursuant to section 713(6) of the *Corporations Act 2001* (Cth) ("**Corporations Act**") restricting TBG Diagnostics Limited ("**TDL**" or "**Company**") from relying on the exceptions in section 713 to use transaction-specific disclosure until 11 March 2022.

TDL clarifies that this restriction means that the Company will not be able to rely on the reduced disclosure rules under section 713 and instead must issue a full prospectus in order to raise funds from certain investors. This restriction will not affect the operation and business of TDL.

ASIC's decision is based on its delegate's view that TDL breached the provisions of Chapter 2M of the Corporations Act as the Company failed to lodge its financial report for the year ending 31 December 2019 by 31 March 2020.

ASIC did not accept the Company's submissions that mitigating circumstances existed which prevented it from complying with Chapter 2M of the Corporations Act.

After being informed that the report would be delayed, TDL applied to both ASX and ASIC on 27 March 2020 and 3 April 2020 respectively for an extension of time in which to lodge the report. ASIC refused the application for the reason that the application did not meet the application requirements for financial reports and audit relief. ASX did not grant an extension of time for TDL to lodge its audited financial report and annual report under Listing Rules 4.5 and 4.7.

TDL paid the late lodgment fee to ASIC and lodged the report on 15 June 2020.

Authorised by the Board of Directors  
Jitto Arulampalam  
Chairman